Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study.
Semaglutide
body composition
glucagon-like peptide-1 receptor agonist
obesity
real-life study
type 2 diabetes
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
10 Jun 2022
10 Jun 2022
Historique:
received:
12
05
2022
revised:
06
06
2022
accepted:
08
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body composition in patients with T2D. Forty patients with T2D were treated with subcutaneous Semaglutide and evaluated at the baseline (T0) and after three (T3) and six (T6) months. Body composition was assessed by a phase-sensitive bioimpedance analyzer. Visceral adipose tissue (VAT) thickness was also measured with an ultrasonographic method (US-VAT). Anthropometric variables, muscular strength, and laboratory tests were analyzed and compared. A significant decrease in VAT, the fat mass index (FMI), and BW loss was observed at all observation times. US-VAT, the skeletal mass index (SMI), the fat-free mass index (FFMI), waist circumferences, and glycated hemoglobin had lessened after three months and remained stable at T6. No variations in muscle strength, the muscle quality index, and body water were found. In a real-life setting, Semaglutide provided significant weight loss mainly due to a reduction in the FMI and VAT, with non-clinically relevant changes in the SMI, the FFMI, and muscle strength. Most importantly, the results were obtained after three months of treatment and persisted thereafter.
Sections du résumé
BACKGROUND
BACKGROUND
Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their effect on body composition has not yet been fully explored. The study aim was to assess the impact of Semaglutide on body composition in patients with T2D.
METHODS
METHODS
Forty patients with T2D were treated with subcutaneous Semaglutide and evaluated at the baseline (T0) and after three (T3) and six (T6) months. Body composition was assessed by a phase-sensitive bioimpedance analyzer. Visceral adipose tissue (VAT) thickness was also measured with an ultrasonographic method (US-VAT). Anthropometric variables, muscular strength, and laboratory tests were analyzed and compared.
RESULTS
RESULTS
A significant decrease in VAT, the fat mass index (FMI), and BW loss was observed at all observation times. US-VAT, the skeletal mass index (SMI), the fat-free mass index (FFMI), waist circumferences, and glycated hemoglobin had lessened after three months and remained stable at T6. No variations in muscle strength, the muscle quality index, and body water were found.
DISCUSSION
CONCLUSIONS
In a real-life setting, Semaglutide provided significant weight loss mainly due to a reduction in the FMI and VAT, with non-clinically relevant changes in the SMI, the FFMI, and muscle strength. Most importantly, the results were obtained after three months of treatment and persisted thereafter.
Identifiants
pubmed: 35745144
pii: nu14122414
doi: 10.3390/nu14122414
pmc: PMC9227575
pii:
doi:
Substances chimiques
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
semaglutide
53AXN4NNHX
Glucagon-Like Peptides
62340-29-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Diabetes Care. 2019 Feb;42(2):331-340
pubmed: 30665965
J Biomed Biotechnol. 2010;2010:476279
pubmed: 20445742
Curr Diabetes Rev. 2021;17(3):293-303
pubmed: 32628589
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Front Physiol. 2013 Mar 25;4:47
pubmed: 23532370
Diabetol Metab Syndr. 2016 Nov 11;8:73
pubmed: 27843495
BMJ. 2012 Jan 10;344:d7771
pubmed: 22236411
Nutrients. 2021 Oct 18;13(10):
pubmed: 34684640
Nutrients. 2020 May 03;12(5):
pubmed: 32375231
Eur J Clin Nutr. 2013 Jan;67 Suppl 1:S14-21
pubmed: 23299866
AJR Am J Roentgenol. 2007 Dec;189(6):1545-53
pubmed: 18029899
BMJ Open Diabetes Res Care. 2020 Oct;8(2):
pubmed: 33115821
Am J Cardiol. 2016 Apr 15;117(8):1355-60
pubmed: 26949037
Diabetes Metab. 2020 Apr;46(2):100-109
pubmed: 31539622
Front Endocrinol (Lausanne). 2020 Aug 25;11:568
pubmed: 32982969
Age Ageing. 2011 Jul;40(4):423-9
pubmed: 21624928
Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
Diabetes Res Clin Pract. 2018 Sep;143:88-100
pubmed: 29944969
N Engl J Med. 2017 Apr 13;376(15):1492
pubmed: 28402780
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2291-2301
pubmed: 29688502
Cardiovasc Diabetol. 2021 Sep 15;20(1):189
pubmed: 34526024
Compr Physiol. 2018 Dec 13;9(1):1-58
pubmed: 30549014
Environ Health Prev Med. 2018 May 17;23(1):20
pubmed: 29776338
Diabetes Obes Metab. 2018 Sep;20(9):2210-2219
pubmed: 29766634
Diabetes Care. 2011 Jul;34(7):1481-6
pubmed: 21593294
Diabetologia. 2020 Mar;63(3):473-485
pubmed: 31897524
Nutrients. 2020 Mar 12;12(3):
pubmed: 32178373
Front Cardiovasc Med. 2020 Feb 25;7:22
pubmed: 32158768
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143
pubmed: 34964831
Pharmacol Res. 2021 Sep;171:105782
pubmed: 34302978
Eur J Clin Nutr. 2017 Sep;71(9):1061-1067
pubmed: 28327564
Prog Mol Biol Transl Sci. 2014;121:133-63
pubmed: 24373237